Lantern Pharma (LTRN) Tops Q2 EPS by 2c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Ennis (EBF) Misses Q2 EPS by 2c
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'